PIERRE FABRE MEDICAMENT

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Preliminary Pharmacokinetics and Bronchodilator Properties of V0162

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Bronchodilatator

First Posted Date: 2011-05-05

Last Posted Date: 2013-06-04

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 108

Registration Number: NCT01348555

Locations: 🇧🇪
SGS, Anvers, Belgium
🇫🇷
SGS Aster SAS, Paris, France

Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Vinflunine plus Capecitabine
Drug: Capecitabine

First Posted Date: 2010-03-29

Last Posted Date: 2022-04-28

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 770

Registration Number: NCT01095003

Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer
Metastases

Interventions: Drug: Alkylating agent of physician choice registered in cancer
Drug: vinflunine

First Posted Date: 2010-03-23

Last Posted Date: 2019-09-16

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 594

Registration Number: NCT01091168

FMS European Long-Term Study

Phase 3

Completed

Conditions: Fibromyalgia Syndrome

Interventions: Drug: milnacipran
Drug: Placebo

First Posted Date: 2008-09-23

Last Posted Date: 2013-07-11

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 490

Registration Number: NCT00757731

Locations: 🇷🇴
Dr I CANTACUZINO CLINICAL HOSPITAL, Bucharest, Romania
🇨🇿
Rheumatology Ambulance, Pardubice, Czech Republic
🇫🇮
Kuopion Oma Laakari Oy, Kuopio, Finland

and more 7 locations

Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran

Phase 2

Completed

Conditions: Fibromyalgia Syndrome

Interventions: Drug: Placebo
Drug: Milnacipran

First Posted Date: 2008-09-23

Last Posted Date: 2013-07-11

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 153

Registration Number: NCT00757679

Locations: 🇨🇭
Clinical Pharmacology & Toxicology Multidisciplinary Pain Centre, Geneve, Switzerland

Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer

Phase 3

Completed

Conditions: NSCLC

Interventions: Drug: Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)

First Posted Date: 2008-05-23

Last Posted Date: 2016-10-04

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 201

Registration Number: NCT00683514

Locations: 🇩🇪
Pierre Fabre Pharma GmbH, Freiburg, Jechtinger Str. 13, Germany

A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome

Phase 3

Completed

Conditions: Fibromyalgia Syndrome

Interventions: Drug: Placebo
Drug: milnacipran

First Posted Date: 2007-02-16

Last Posted Date: 2013-07-11

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 1429

Registration Number: NCT00436033

Locations: 🇨🇿
Rheumatology Ambulance, Pardubice, Czech Republic
🇩🇰
FREDERIKSBERG HOSPITAL - Clinic of Rheumatology, Frederiksberg, Denmark
🇮🇹
Ospedale Luigi Sacco, Milano, Italy

and more 10 locations

Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract

Phase 3

Completed

Conditions: Transitional Cell Carcinoma of the Urothelial Tract
Bladder Cancer
Bladder Neoplasms

Interventions: Drug: vinflunine and best supportive care

First Posted Date: 2006-04-18

Last Posted Date: 2010-01-07

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 364

Registration Number: NCT00315237

Locations: 🇨🇦
Local Institution, Montreal, Quebec, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy